Monthly alternating injections of aflibercept and bevacizumab for neovascular age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004247

Enrollment

Registered

2019-08-27

Start date

2019-05-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Monthly alternating injections of aflibercept and bevacizumab (MAAB) for maintenance treatment in patients with neovascular age-related macular degeneration (AMD) who showed improvements with t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: neovascular AMD diagnosed by fundoscopy, optical coherence tomography (OCT), and fluorescein and indocyanine green (ICG) angiography between March 2016 and March 2017

Exclusion criteria

Exclusion criteria: We excluded patients with a history of vitrectomy, laser photocoagulation, or photodynamic therapy (PDT), as well as those with other retinal diseases such as angioid streaks, vitelliform macular dystrophy, and retinal vein or artery occlusion.

Design outcomes

Primary

Measure	Time frame
Visual acuity	—

Secondary

Measure	Time frame
retinal thickness	—

Countries

Korea, Republic of

Contacts

Public Contactjunyeop Lee

Yeongnam University Medical Center

mdjylee@gmail.com+82-53-640-6960

Outcome results